Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.81 |
| ▸ | MAPT | P10636 | 3/20 | 0.81 |
| ▸ | MEN1 | O00255 | 2/20 | 0.81 |
| ▸ | BLM | P54132 | 2/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.81 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.81 |
| ▸ | GLA | P06280 | 1/20 | 0.81 |
| ▸ | RECQL | P46063 | 1/20 | 0.81 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.81 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.81 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.81 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.81 |
| ▸ | TOP1 | P11387 | 3/20 | 0.63 |
| ▸ | TOP2A | P11388 | 3/20 | 0.63 |
| ▸ | BRD4 | O60885 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1059266 | 1.00 | ALDH1A1 (0.81) | ALDH1A1SMN1; SMN2MAPTMEN1BLM | |
| Hydrochloric Acid SCHEMBL6850585 | 0.99 | ALDH1A1 (0.79) | ALDH1A1SMN1; SMN2MAPTMEN1BLM | |
| Hydrochloric Acid SCHEMBL29728780 | 0.99 | ALDH1A1 (0.79) | ALDH1A1SMN1; SMN2MAPTMEN1BLM | |
| Hydrochloric Acid SCHEMBL38685 | 0.99 | ALDH1A1 (0.79) | ALDH1A1SMN1; SMN2MAPTMEN1BLM | |
| Hydrochloric Acid SCHEMBL659782 | 0.99 | ALDH1A1 (0.79) | ALDH1A1SMN1; SMN2MAPTMEN1BLM | |
| Hydrochloric Acid SCHEMBL4950608 | 0.98 | ALDH1A1 (0.78) | ALDH1A1SMN1; SMN2MAPTMEN1BLM | |
| Hydrochloric Acid SCHEMBL15545820 | 0.98 | ALDH1A1 (0.78) | ALDH1A1SMN1; SMN2MAPTMEN1BLM | |
| Hydrochloric Acid SCHEMBL4538254 | 0.98 | ALDH1A1 (0.78) | ALDH1A1SMN1; SMN2MAPTMEN1BLM | |
| SCHEMBL15969230 | 0.95 | ALDH1A1 (0.90) | ALDH1A1SMN1; SMN2MAPTMEN1BLM | |
| Hoechst 33258 SCHEMBL6942659 | 0.93 | ALDH1A1 (0.71) | ALDH1A1SMN1; SMN2MAPTMEN1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3226909-B1 | QUATERNARY AMINE COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH INC (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-3792262-B1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | SANOFI SA (FR) | 2026-04-15 | — | — | EP | disclosed |
| US-20250333412-A1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | SANOFI SA (FR) | 2025-10-30 | — | — | US | disclosed |
| US-12275733-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | SANOFI (FR) | 2025-04-15 | — | — | US | disclosed |
| US-20240182469-A1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | SANOFI (FR) | 2024-06-06 | — | — | US | disclosed |
| US-11931713-B2 | Oligonucleotide data storage on solid supports | Global Life Sciences Solutions Operations UK Ltd (GB) | 2024-03-19 | — | — | US | disclosed |
| US-11827633-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | SANOFI (FR) | 2023-11-28 | — | — | US | disclosed |
| EP-3843725-B1 | COMPOUND FOR USE IN THE TREATMENT OF A DISEASE CHARACTERIZED BY DYSREGULATED MUCUS PRODUCTION AND/OR SECRETION | UNIV REGENSBURG (DE) | 2023-09-06 | — | — | EP | disclosed |
| EP-3966575-B1 | CYSTIC FIBROSIS URINE TEST | UNIV AARHUS (DK) | 2023-08-23 | — | — | EP | disclosed |
| CN-116622828-A | Primer and probe composition for guiding medication of depression and detection kit | 深圳会众生物技术有限公司 | 2023-08-22 | — | — | CN | disclosed |
| US-20230009145-A1 | INHIBITION OF TMEM16A BY BENZBROMARONE OR NICLOSAMIDE FOR TREATING POLYCYSTIC KIDNEY DISEASE AND/OR POLYCYSTIC LIVER DISEASE | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2023-01-12 | — | — | US | disclosed |
| US-20220304993-A1 | CONJUGATES OF AN ELECTRON-DONATING NITROGEN OR TERTIARY AMINE COMPRISING COMPOUNDS | ASCENDIS PHARMA A/S (DK) | 2022-09-29 | — | — | US | disclosed |
| EP-4054555-A1 | INHIBITION OF TMEM16A BY BENZBROMARONE OR NICLOSAMIDE FOR TREATING POLYCYSTIC KIDNEY DISEASE AND/OR POLYCYSTIC LIVER DISEASE | Universität Regensburg (DE) | 2022-09-14 | — | — | EP | disclosed |
| CN-110382496-B | Substituted pyrido [3,4-b ] indoles for the treatment of cartilage disorders | 赛诺菲 | 2022-08-09 | — | — | CN | disclosed |
| US-20220206013-A1 | CYSTIC FIBROSIS URINE TEST | UNIVERSITY OF REGENSBURG (DE) | 2022-06-30 | — | — | US | disclosed |
| CN-114544567-A | Fluorescent probe combination for detecting cell apoptosis and method for realizing cell apoptosis detection by using double fluorescent markers | 贵州医科大学附属医院 | 2022-05-27 | — | — | CN | disclosed |
| EP-3986471-A1 | CONJUGATES OF AN ELECTRON-DONATING NITROGEN OR TERTIARY AMINE COMPRISING COMPOUNDS | Ascendis Pharma A/S (DK) | 2022-04-27 | — | — | EP | disclosed |
| EP-3966575-A1 | CYSTIC FIBROSIS URINE TEST | Aarhus Universitet (DK) | 2022-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827633-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | COL2A1, IDO1, COL1A1 | ALDH1A1 465/4885SMN1; SMN2 3147/4885MAPT 4099/4885 |
| US-20240182469-A1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | COL2A1, IDO1, COL1A1 | ALDH1A1 465/4885SMN1; SMN2 3147/4885MAPT 4099/4885 |
| US-12275733-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | COL2A1, IDO1, COL1A1 | ALDH1A1 465/4885SMN1; SMN2 3147/4885MAPT 4099/4885 |
| US-20250333412-A1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | COL2A1, IDO1, COL1A1 | ALDH1A1 415/4885SMN1; SMN2 3103/4885MAPT 4116/4885 |
| US-20220304993-A1 | CONJUGATES OF AN ELECTRON-DONATING NITROGEN OR TERTIARY AMINE COMPRISING COMPOUNDS | NQO1, HNMT, PNMT | ALDH1A1 288/4885SMN1; SMN2 2602/4885MAPT 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.